Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 114.15 -0.05 (-0.04%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Class Action Launched Concerning Johnson & Johnson Discontinuance of Several ...
These Johnson & Johnson Mesh products were marketed to correct Stress Urinary Incontinence and Pelvic Organ Prolapse. Health Canada first licensed the products for sale and use in Canada on August 19, 1998.
Johnson & Johnson to stop selling surgical mesh  Fox News
Johnson & Johnson Unit to Halt Urinary Implants  New York Times
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Cramer: Johnson & Johnson Could Unlock Value by Splitting Up
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson Announces Completion of Synthes Acquisition
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate  Forbes
Johnson & Johnson completes $20B takeover of Synthes  Bizjournals.com
Johnson & Johnson: A Lucrative Buy On Synthes Acquisition
Johnson & Johnson (NYSE:JNJ) just announced that it has completed the acquisition of Synthes. The company is the world's largest maker of implants to mend bone fractures and also producer of surgical power tools and advanced biomaterials.
Johnson & Johnson kept selling vaginal mesh implants after warnings
Johnson & Johnson continued to sell a vaginal mesh implant for nine months after U.S. regulators told the company to stop marketing the device, according to court records.
Toyota, Johnson & Johnson, Honda Top Global Green Brands Ranking
Toyota, Johnson & Johnson, Honda, Volkswagon and Hewlett-Packard topped an annual ranking of global green brands by consultancy firm Interbrand.
Toyota, Honda, Volkswagen Named Greenest Global Car Brands by Interbrand  brandchannel.com
Polaris, J&J Idea to Solve Drug R&D Crisis: Work Together Early
... there are also a lot of experiments going on now to find ways to reform the way drug companies and venture capitalists work together.
J&J, Polaris pact follows series of pharma/VC combos  FierceBiotech